These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
These initiatives aim to improve access to healthcare for rare disease patients
Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3%
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
The Niti Aayog and the DoP had listed a few factors that were leading to a 10-15% disability factor to be globally competitive
The facility will have a capacity to manufacture upto 3 million tubes monthly
Subscribe To Our Newsletter & Stay Updated
